The neutralization of VEGF is the current treatment of choice for age-related macular degeneration. Current approaches include anti-VEGF-antibodies and – Fab Fragments, aptamers, soluble receptors (Traps) and siRNA. The molecular properties of VEGF and its antagonists are reviewed and the pathways of action of these substances are discussed.
Keywords: VEGF, ranibizumab, lucentis, AMD, pegaptanib, VEGF-trap
Rights & PermissionsPrintExport